 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | BITR2101 / Boston Immune Tech
New P1 trial: A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System (clinicaltrials.gov) - Apr 25, 2024
P1, N=37, Not yet recruiting, Sponsor: Boston Immune Technologies and Therapeutics